↓ Skip to main content

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

Overview of attention for article published in BMC Cancer, April 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news
1 news outlet
policy
1 policy source

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
33 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
Published in
BMC Cancer, April 2018
DOI 10.1186/s12885-018-4308-7
Pubmed ID
Authors

Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang, Ming Kuang

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 33 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 21%
Student > Doctoral Student 5 15%
Student > Bachelor 5 15%
Student > Postgraduate 4 12%
Student > Ph. D. Student 2 6%
Other 4 12%
Unknown 6 18%
Readers by discipline Count As %
Medicine and Dentistry 10 30%
Nursing and Health Professions 4 12%
Pharmacology, Toxicology and Pharmaceutical Science 3 9%
Biochemistry, Genetics and Molecular Biology 2 6%
Business, Management and Accounting 1 3%
Other 5 15%
Unknown 8 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 November 2020.
All research outputs
#3,013,987
of 23,248,929 outputs
Outputs from BMC Cancer
#662
of 8,423 outputs
Outputs of similar age
#64,276
of 330,173 outputs
Outputs of similar age from BMC Cancer
#30
of 223 outputs
Altmetric has tracked 23,248,929 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,423 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 330,173 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 223 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.